A review of cellular therapies for chronic lymphocytic leukemia

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 2, 2014, Pages 164-167

  Tomblyn, Marcie Riches ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Allogeneic transplantation; Autologous transplantation; Cellular therapy; Chronic lymphocytic leukemia (CLL)

Indexed keywords

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CELL THERAPY; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; OVERALL SURVIVAL; REVIEW; TREATMENT OUTCOME;

ALLOGENEIC TRANSPLANTATION; AUTOLOGOUS TRANSPLANTATION; CELLULAR THERAPY; CHRONIC LYMPHOCYTIC LEUKEMIA (CLL);

HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84893651750     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.11.023     Document Type: Review

References (21)

1. Byrd J.C., Furman R.R., Coutre S.E., et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. NEng J Med 2013, 369:32-42.
2. Dreger P., Stilgenbauer S., Benner A., et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. Blood 2004, 103:2850-2858.
3. Michallet M., Dreger P., Sutton L., et al. Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation. Blood 2011, 117:1516-1521.
4. Sutton L., Chevret S., Tournilhac O., et al. Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC. Blood 2011, 117:6109-6119.
5. Brion A., Mahe B., Kolb B., et al. Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial. Bone Marrow Transplant 2012, 47:542-548.
6. Dreger P., Döhner H., McClanahan F., et al. Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial. Blood 2012, 119:4851-4859.
7. Hallek M., Fischer K., Fingerle-Rowson G., et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376:1164-1174.
8. Gribben J.G. Stem cell transplantation in chronic lymphocytic leukemia. Biol Blood Marrow Transplant 2009, 15(1 Suppl):53-58.
9. Dreger P., Corradini P., Kimby E., et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007, 21:12-17.
10. Malhotra P., Hogan W.J., Litzow M.R., et al. Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years. Leuk Lymphoma 2008, 49:1724-1730.
11. Schetelig J., van Biezen A., Brand R., et al. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. JClin Oncol 2008, 26:5094-5100.
12. Sorror M.L., Storer B.E., Sandmaier B.M., et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. JClin Oncol 2008, 26:4912-4920.
13. Khouri I.F., Bassett R., Poindexter N., et al. Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. Cancer 2011, 117:4679-4688.
14. Machaczka M., Johansson J.E., Remberger M., et al. Allogeneic hematopoietic stem cell transplant with reduced-intensity conditioning for chronic lymphocytic leukemia in Sweden: does donor T-cell engraftment 3 months after transplant predict survival?. Leuk Lymphoma 2012, 53:1699-1705.
15. McClune B.L., Defor T., Brunstein C., et al. Reduced intensity allogeneic haematopoietic cell transplantation for chronic lymphocytic leukaemia: related donor and umbilical cord allografting. Br J Haematol 2012, 156:273-275.
16. Kharfan-Dabaja M.A., Anasetti C., Fernandez H.F., et al. Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting. Biol Blood Marrow Transplant 2013, 19:1087-1093.
17. Khouri I.F., Saliba R.M., Admirand J., et al. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 2007, 137:355-363.
18. Cwynarski K., van Biezen A., de Wreede L., et al. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): a retrospective analysis from the Chronic Lymphocytic Leukemia Subcommittee of the Chronic Leukemia Working Party and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. JClin Oncol 2012, 30:2211-2217.
19. Kharfan-Dabaja M.A., Pidala J., Kumar A., et al. Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis. Bone Marrow Transplant 2012, 47:1164-1170.
20. Porter D.L., Levine B.L., Kalos M., et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. NEng J Med 2011, 365:725-733.
21. Burkhardt U.E., Hainz U., Stevenson K., et al. Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. JClin Invest 2013, 123:3756-3765.